Steven E. Hyman, M.D.

Harvard Department of Stem Cell and Regenerative Biology
The Broad Institute
Steven E Hyman, HSCI
shyman@fas.harvard.edu
Stanley Center for Psychiatric Research
Steven Hyman publications
Q-State Biosciences

Steven E Hyman is the Harald McPike Professor of Stem Cell and Regenerative Biology, Harvard University Distinguished Service Professor and a Core Institute Member of the Broad Institute of MIT and Harvard where he directs the Broad Program in Brain Health. He is principal investigator of the Psychiatric Biomarkers Network (PBN), a multisite academic-industry consortium discovering fluid biomarkers for schizophrenia-bipolar spectrum disorders and creating a repository for sharing data and samples.

From 2001 to 2011 Hyman served as Harvard University Provost (chief academic officer) with a special focus on building interdisciplinary collaborations, including internationally. From 1996 to 2001 he was Director of the US National Institute of Mental Health (NIMH) where he modernized its research portfolio, emphasizing neuroscience, emerging genomic technologies, and initiating a series of large pragmatic clinical trials to inform practice. He has served as Editor of the Annual Review of Neuroscience (2002-2016), founding President of the International Neuroethics Society (2008-2013), President of the Society for Neuroscience (2015), and President of the American College of Neuropsychopharmacology (2018).  He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine (NAM) where he chaired the Forum on Neuroscience and Nervous System Disorders (2012-2018), served on the NAM governing Council (2012-2018) and on the governing board of the National Research Council, the operating arm of the National Academies of Sciences, Engineering, and Medicine (2016-2019).  He chairs the Boards of Directors of the Charles A. Dana Foundation (NY) and the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland). In the private sector he is a Director of Voyager Therapeutics and Vesalius Therapeutics, and a founder of Emugen Therapeutics.  He serves on the Scientific Advisory Boards of J&J Innovative Medicines and F-Prime Capital. He received his BA, summa cum laude, from Yale, an MA from the University of Cambridge, where he was a Mellon fellow studying History and Philosophy of Science, and an MD, cum laude, from Harvard Medical School.